Abalos Therapeutics to Present Preclinical Data on Combination Therapy

Düsseldorf, Germany – Abalos Therapeutics announced on November 4, 2025, that it will present new preclinical data highlighting the potential of its candidate ABX-001 in combination with bispecific T-cell engagers at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.

Professor Karl S. Lang will present the data during a poster session on Saturday, November 8. ABX-001 is Abalos' lead candidate, which has demonstrated robust anti-cancer activity in a range of solid tumor models. The company recently announced the initiation of a Phase 1 first-in-human study to evaluate ABX-001 as a monotherapy in patients with refractory or relapsed advanced solid tumors.

"By harnessing the natural process of mutation and selection combined with targeted virus engineering, we have created an immunotherapy with highly differentiating immunostimulatory and anti-tumoral properties," said Jörg Vollmer, CSO at Abalos. "This new preclinical data shows that ABX-001 works hand-in-hand with T-cell directed therapies like bispecific T-cell engagers to create a powerful synergistic anti-tumor response."

The data shows that ABX-001, based on an optimized arenavirus strain, replicates selectively in tumor cells with minimal effects on healthy tissues. The treatment recruits, activates, and expands CD8+ T-cells, increasing their infiltration into the tumor and differentiating them into potent effector cells for fighting cancer. When combined with a bispecific T-cell engager, ABX-001 produced synergistic anti-tumor effects, significantly enhancing T-cell recruitment and cytotoxic activity against tumor cells compared to bispecific T-cell engager therapy alone.

Abalos Therapeutics is pioneering a novel anti-cancer approach that directs the immune system's power specifically towards cancer cells. The company's arenavirus-based candidates are designed to trigger precise innate and adaptive immune responses from within the tumor. A Phase 1 study evaluating ABX-001 is underway for multiple solid tumor types.